Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Activation Immunotherapies

Immunotherapy: The Future of Lung Cancer Treatment?

Immunotherapy: Past, Present and Future

Adoptive T Cell Therapy Applications

Suppression Immunotherapies

Immunotherapy and Helminthic Therapy

Adoptive T Cell Therapy Methodology

Neoantigens' Role in Immunotherapy

Latest Immunotherapy News and Research

CAR T-cell therapy shows promise for difficult-to-treat lupus

A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from researchers at Hospital for Special Surgery (HSS).

8 Nov 2026

Seasonal allergies may be driving recurrent sinus infections

"Every spring, I get sick. Then it happens again in the fall." If you have frequent sinus symptoms that follow a seasonal pattern, allergies may be the root cause. Seasonal allergies can cause congestion, drainage, facial pressure, and fatigue.

6 Nov 2026

NIH award supports research into ovarian cancer and neural connections

One of the biggest breakthroughs in modern cancer treatment doesn't attack cancer directly. Instead, immunotherapy harnesses the body's immune system to recognize and destroy cancer cells.

6 Nov 2026

Harvard-led team receives $7 million to develop AI co-scientists for cancer research

A team led by Marinka Zitnik, associate professor of biomedical informatics in the Blavatnik Institute at Harvard Medical School, has received a grant of nearly $7 million from Cancer Grand Challenges to create artificial intelligence (AI) "co-scientists" that help cancer researchers analyze data, generate hypotheses, and suggest new experiments, speeding new knowledge and therapies.

6 Nov 2026

Towards a new approach to treating chronic blood disorders

A previously unrecognised weakness in the immune defenses against certain blood neoplasms could offer a promising target for future treatments.

6 Nov 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that two abstracts highlighting real-world clinical outcomes for Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, USA, December 12–15, 2026.

6 Nov 2026

Rising colorectal cancer rates prompt earlier routine screening recommendations

Forty-five is the new 60 – at least when it comes to colonoscopies. That may not be the party you look forward to, but it could save your life. According to the Cancer Research Institute, 1 in 5 colorectal cancers are diagnosed in patients under age 55, making what was once thought of as an older person's disease one of the fastest-growing cancers in young people.

5 Nov 2026

Organoid coculture platforms enhance preclinical prediction of drug efficacy

Three‐dimensional cancer organoids cultured in vitro closely recapitulate the phenotypic and genetic features of parental tumor tissues, making them powerful tools for cancer research, drug screening, and personalized medicine.

5 Nov 2026

Three-drug combination remodels immune environment in gastric cancer

A triplet combination therapy can remodel the tumor microenvironment in patients with advanced gastric cancer and shows a promising safety profile, according to results from a new phase 2 clinical trial.

5 Nov 2026

Supervised food challenges clear many infants of suspected peanut allergy

A world-first national program has discovered more than a third of babies thought to have a peanut allergy could safely have the diagnosis removed. And the findings are changing how Australia's healthcare system approaches infant food allergies.

4 Nov 2026

AlphaFold3 reveals molecular interactions driving T cell recognition

Researchers at the Translational Genomics Research Institute (TGen), part of City of Hope, have developed a new approach using the artificial intelligence platform AlphaFold3 to predict whether a T cell receptor will recognize a specific antigen based solely on its genetic sequence.

3 Nov 2026

Engineered beneficial bacteria reduce bloodstream infections after stem cell transplants

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the country, and collaborators have pioneered a new approach to preventing dangerous bloodstream infections in patients receiving donor stem cell transplants for blood cancers.

3 Nov 2026

Immunotherapy reshapes immune cell interactions in melanoma-affected lymph nodes

A new study from Mayo Clinic suggests checkpoint immunotherapy may reshape the immune environment within lymph nodes after melanoma has spread to them.

30 Oct 2026

Hyperactive cancer-promoting proteins help tumor cells evade immune attack

The immune system may recognize a cancer cell and still fail to destroy it. Researchers at Hiroshima University and their international collaborators found that hyperactive YAP and TAZ (YAP/TAZ), two cancer-promoting proteins, were associated with genomic instability that may make cancer cells more recognizable to the immune system, while also increasing PD-L2, which helps the cells suppress T-cell attack.

30 Oct 2026

Targeting specific enzyme reverses radiation-induced immune suppression in cancer

Researchers at the University of Chicago identified a mechanism to make immune cells reprogrammed by radiation therapy attack tumors rather than protect them.

30 Oct 2026

Researchers find simple way to boost engineered T-cell therapies

Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a promising new strategy to make cancer-fighting immune cells stronger and potentially longer-lasting, a discovery that could help improve the effectiveness of immunotherapies that use a patient's own immune cells to attack cancer.

29 Oct 2026

Mutated neutrophils may trigger immune attacks in lupus

Scientists at La Jolla Institute for Immunology (LJI) and the University of Washington (UW) have discovered that patients with lupus have unusual mutations that may turn their bodies into battlegrounds.

28 Oct 2026

Dual-targeting antibody successfully tackles multiple tumor types in mice

A novel antibody therapy empowers the immune system's tumor-fighting capabilities in mice by targeting immune-suppressing T cells with greater precision than previous approaches, according to new work.

28 Oct 2026

Targeted drug combination extends survival in advanced kidney cancer

Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.

28 Oct 2026

Lab-on-a-chip technology helps predict childhood leukemia treatment responses

More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children.

27 Oct 2026